Shalini Mulaparthi – Oncology ...

Dr. Shalini Mulaparthi

Claim this profile

The Watson Clinic

Studies Breast Cancer
Studies Breast cancer
5 reported clinical trials
20 drugs studied

Area of expertise

1Breast Cancer
Shalini Mulaparthi has run 4 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive
2Breast Cancer
Shalini Mulaparthi has run 3 trials for Breast cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Affiliated Hospitals

Image of trial facility.
The Watson Clinic

Clinical Trials Shalini Mulaparthi is currently running

Image of trial facility.

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria

More about Shalini Mulaparthi

Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Shalini Mulaparthi has experience with
  • Usual Care Disease Monitoring
  • Serum Tumor Marker Directed Disease Monitoring
  • Radiation
  • Tamoxifen
  • Anastrozol
  • Letrozole

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Shalini Mulaparthi specialize in?
Is Shalini Mulaparthi currently recruiting for clinical trials?
Are there any treatments that Shalini Mulaparthi has studied deeply?
What is the best way to schedule an appointment with Shalini Mulaparthi?
What is the office address of Shalini Mulaparthi?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security